KalVista Pharmaceuticals (NasdaqGM:KALV) Earnings call March 25, 2026 08:30 AM ET Company ParticipantsAmy Li - SVP Equity Research of Biotechnology and Large Cap PharmaBen Palleiko - CEO and DirectorBrian Piekos - CFOJulian Pino - Senior Associate of Biotechnology Equity ResearchNicole Sweeny - Chief Commercial OfficerPaul Audhya - Chief Medical OfficerRyan Baker - Head of Investor RelationsStacy Ku - Biotechnology Equity ResearchTazeen Ahmad - Managing Director in US Equity ResearchConference Call Particip ...

Exhibit 99.1 KalVista Pharmaceuticals Reports Eight Months Fiscal Year 2025 Financial Results and Provides Corporate Update $49.1 million global net product revenue of EKTERLY® (sebetralstat) for the eight months ended December 31, 2025 1,702 patient start forms received in the US from launch through end of February, reflecting continued rapid adoption of first and only oral on-demand treatment for hereditary angioedema (HAE) EKTERLY launched in Japan by partner Kaken Pharmaceutical Co., LTD Company to host ...

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

FRAMINGHAM, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced that five abstracts, including one late-breaking submission, have been accepted for presentation at the 2026 Global Angioedema Leadership Conference taking place in Madrid, Spain from March 26–29, 2026. The following late-breaking abstract will be presented during the poster session on Friday, March 27 and as an oral presentation on Saturday, March 28 at 11:50 am CET: On-demand. ...

Group 1 - KalVista Pharmaceuticals, Inc. (KALV) shares have increased following FDA approval of its HAE therapy Ekterly, which is the first oral on-demand treatment for HAE attacks [2] - Since receiving FDA approval in July 2025, Ekterly has generated revenue for the company [2] - The Biotech Forum, led by Bret Jensen, offers a model portfolio of 12-20 high upside biotech stocks and provides market commentary and portfolio updates weekly [2]

Core Insights - KalVista Pharmaceuticals (KALV) stock has seen an increase in its Relative Strength (RS) Rating from 79 to 86, indicating improved market leadership potential [1] - The stock is currently forming a cup without handle pattern with a potential entry point at $19.00, and a breakout is anticipated if trading volume exceeds 40% above average [1] - The latest quarterly report shows 0% earnings growth and 0% sales growth for KalVista Pharmaceuticals, placing it at No. 195 among peers in the Medical-Biomed/Biotech industry group [1] Company Performance - KalVista Pharmaceuticals has an RS Rating of 86, which is considered strong as stocks with an RS Rating of 80 or higher typically perform well during significant price movements [1] - The company is currently experiencing stagnant earnings and sales growth, both reported at 0% in the latest quarter [1] Industry Context - Within the Medical-Biomed/Biotech industry group, KalVista ranks No. 195, with Kiniksa Pharmaceuticals (KNSA), Aurinia Pharmaceuticals (AUPH), and Incyte (INCY) being among the top-rated stocks [1] - The article suggests monitoring the biotech sector for potential investment opportunities, highlighting the importance of volume in stock performance [1]

Summary of KalVista Pharmaceuticals FY Conference Call Company Overview - **Company**: KalVista Pharmaceuticals (NasdaqGM: KALV) - **Product**: Ekterly, the first and only oral therapy for the on-demand treatment of hereditary angioedema (HAE) attacks, approved in July 2025 [2][4] Key Points and Arguments Product Launch and Performance - **Launch Success**: Ekterly's commercial launch has exceeded expectations, with positive feedback from physicians and patients [2][8] - **Patient Satisfaction**: Approximately 90% satisfaction reported among patients and physicians within the first 7 months of launch [8] - **Market Penetration**: The drug is attracting patients from existing on-demand therapies, particularly from Ruconest, and is seeing a higher-than-expected conversion rate [10][11] Clinical Data and Education - **Clinical Trials**: KalVista conducted the largest Phase 2 and Phase 3 trials in HAE, demonstrating strong efficacy and safety [3][4] - **Educational Efforts**: Extensive outreach to physicians and the patient community has established KalVista as a thought leader in HAE treatment [5][6] Patient Support Services - **QuickStart Program**: Aimed at facilitating patient access to Ekterly, allowing for immediate shipment upon prescription approval [20][21] - **Refill Dynamics**: Patients are refilling Ekterly more frequently than anticipated, with an average of two cartons every two months, indicating higher usage rates [26][45] Market Dynamics - **High Burden Patients**: Approximately 20% of HAE patients experience two or more attacks per month, representing a significant market opportunity [34] - **Payer Dynamics**: Payers are currently accommodating high-burden patients, with limited restrictions on Ekterly access expected in the future [39] Future Growth and Strategy - **Pediatric Approval**: Plans to file for pediatric approval (ages 2-11) in Q3 2026, expanding the potential patient base [62] - **Short-term Prophylaxis**: Development of data to support Ekterly's use in short-term prophylaxis for procedures that may trigger attacks [63] - **Market Size**: The total addressable market (TAM) for HAE on-demand therapies is estimated at $1.5 billion, with current sales below $700 million due to a heavily genericized market [65][66] Financial Metrics - **Revenue Performance**: $35 million in Q4 and $49 million since launch, with refill revenue surpassing new patient starts [42][45] - **Gross-to-Net Expectations**: Anticipated gross-to-net ratios in the high teens to low twenties, consistent with industry standards [50] Additional Important Insights - **Community Engagement**: The patient ambassador program aims to connect patients with others who have similar experiences, enhancing understanding and comfort with Ekterly [58] - **Competitive Landscape**: KalVista is focused on maintaining its first-mover advantage against competitors like Pharvaris by continuing to educate the market on Ekterly's benefits [59][61] This summary encapsulates the key insights from the conference call, highlighting KalVista Pharmaceuticals' strategic positioning, product performance, and future growth opportunities in the HAE market.

Core Viewpoint - KalVista Pharmaceuticals, Inc. (KALV) shows significant upside potential with a mean price target of $33.78, indicating an 117.1% increase from its current trading price of $15.56 [1] Price Targets and Analyst Estimates - The mean estimate consists of nine short-term price targets with a standard deviation of $5.4, where the lowest estimate is $22.00 (41.4% increase) and the highest is $39.00 (150.6% increase) [2] - A low standard deviation suggests strong agreement among analysts regarding the stock's price movement, which can serve as a starting point for further research [9] Earnings Estimates and Analyst Sentiment - Analysts have shown increasing optimism about KALV's earnings prospects, as indicated by a positive trend in earnings estimate revisions [11] - Over the last 30 days, the Zacks Consensus Estimate for the current year has increased by 29.2%, with two estimates moving higher and no negative revisions [12] - KALV holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] Conclusion on Price Movement - While the consensus price target may not be a reliable indicator of the stock's potential gain, the implied direction of price movement appears to be a useful guide [14]

Core Viewpoint - The article emphasizes the value of in-depth analysis in the Biotech sector, highlighting the services offered by Biotech Analysis Central to assist investors in making informed decisions [2]. Group 1: Company Overview - Biotech Analysis Central provides a comprehensive library of over 600 Biotech investing articles, which includes a model portfolio featuring more than 10 small and mid-cap stocks with detailed analyses for each [2]. - The service offers a live chat feature and a variety of analysis and news reports tailored for Healthcare investors [2]. Group 2: Subscription Details - The Biotech Analysis Central service is priced at $49 per month, with a promotional offer of a 33.50% discount for those who opt for the annual plan, bringing the yearly cost to $399 [1].

Core Insights - KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) is recognized as one of the 20 Best Biotech Stocks Under $20 to buy now, ranking twelfth on the list [1] - Analysts from TD Cowen and H.C. Wainwright have raised their price targets for KALV, indicating strong confidence in the company's future performance [2][1] Analyst Ratings - TD Cowen analyst Stacy Ku increased the price target for KALV from $30 to $35 while maintaining a Buy rating, following an update to the financial model ahead of the fourth-quarter results [1] - H.C. Wainwright analyst Andrew Fein raised the price target from $27 to $37, also maintaining a Buy rating, citing confidence from the company's fiscal 2025 EKTERLY revenue [2] Company Overview - KalVista Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing small-molecule protease inhibitors for rare diseases, including hereditary angioedema and diabetic macular edema [3] - The company aims to provide oral and targeted therapies to enhance patient outcomes and quality of life [3]